SEC Form 4 · accession 0001140361-17-032420
Opus Genetics, Inc. · IRD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter David Suzdak
Officer — Chief Executive Officer · Director
Period of report
Aug 16, 2017
Accepted (ET)
Aug 16, 2017 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001228627
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 16, 2017 | A | 10,000 | $1.9872 | A | 16,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price of $1.9872 per share represents a weighted average of purchase prices ranging from $1.96 to $2.01 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.